Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients

NEXT STORY
Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
PREV STORY
Batavia Biosciences Receives $13.2M Grant to Accelerate Market Access of Low-Cost Inactivated Polio Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar

author_avatar
NASDAQ Market News

Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging ...

author_avatar
NASDAQ Market News

RAPT Therapeutics Announces Pricing of $75 Million Public Offering

author_avatar
NASDAQ Market News